131I-MIBG Therapy in a Metastatic Small Bowel Neuroendocrine Tumor Patient Undergoing Hemodialysis

Abstract

Systemic radioisotope therapy with I-metaiodobenzylguanidine (I-MIBG) is an effective form of targeted therapy for neuroendocrine tumors. One of the absolute contraindications to administering I-MIBG therapy listed in the 2008 European Association of Nuclear Medicine guidelines is renal insufficiency requiring dialysis, although this contraindication is not evidence based. We describe a 68-year-old woman with a metastatic small bowel neuroendocrine tumor who developed renal insufficiency requiring hemodialysis. Imaging and dosimetry with I-MIBG were performed and showed that the radiation doses to the whole body and lungs were within safe limits. She was treated with 1820 MBq of I-MIBG with no short-term adverse reactions.

Potential Role of Protein Kinase FAM20C on the Brain in Raine Syndrome, an In Silico Analysis

“…It originates from the dorsal portion of the metencephalon and the neural folds and includes four steps: organization of the cerebellar territory, establishment of cerebellar progenitors (GABAergic and glutamatergic ones), migration of the granule cells, and formation of the cerebellar nuclei and circuitry [58]. The cerebellum neurons are also derived from the ventricular zone, in addition from the rhombic lip [59,60]. Congenital cerebellum defects are present frequently with other neural defects, such as cortical hypoplasia and corpus callosum agenesis, and sometimes are present as isolated defects.…”